U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon ' s Proposed Biosimilar Trastuzumab

HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Jan. 11, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news